Are CME providers being used by the pharmaceutical industry to legitimize a treatment for a condition that isn’t really a disease? Did GlaxoSmithKline “invent” irritable bowel syndrome in part by underwriting CME on the subject? These uncomfortable questions have been raised in a new article appearing in the April 13 issue of the British Medical Journal.
Register to view the full article
Register for MeetingsNet.com and gain access to premium content including the CMI 25 Listing, our monthly digital edition, the MeetingsNet app, live and on-demand webinars, and much more.
0 comments
Hide comments